7536-39-2

Basic information

• Product Name: 3-(benzylsulfanyl)-3-methylbutanoic acid
• Synonyms: 3-(Benzylsulfanyl)-3-methylbutanoic acid; butanoic acid, 3-methyl-3-[(phenylmethyl)thio]-
• CAS NO: 7536-39-2
• Molecular Formula: C₁₂H₁₆O₂S
• Molecular Weight: 224.3192
• Mol File: 7536-39-2.mol

Chemical Properties

• Boiling Point: 362.2°C at 760 mmHg
• Flash Point: 172.9°C
• Density: 1.139g/cm³
• Vapor Pressure: 7E-06mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: 3-(benzylsulfanyl)-3-methylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzylsulfanyl)-3-methylbutanoic acid(7536-39-2)
• EPA Substance Registry System: 3-(benzylsulfanyl)-3-methylbutanoic acid(7536-39-2)

Safety Data

• Hazardous Substances Data: 7536-39-2(Hazardous Substances Data)

Upstream product

• 541-47-9 3-Methylbutenoic acid 
• 100-53-8 phenylmethanethiol 

Downstream Products

• 1313762-25-2 benzyl 2-(3-(benzylthio)-3-methylbutanamido)-2-methylpropanoate 
• 1313762-27-4 N-(2-(2-methyl-2-(benzylthio)propylcarbamoyl)propan-2-yl)-3-methyl-3-(benzylthio)butanamide 
• 1313762-26-3 2-(3-(benzylthio)-3-methylbutanamido)-2-methylpropanoic acid 
• 34300-94-2 3-Methyl-3-sulfanylbutan-1-ol 
• 153893-82-4 (R)-3-Benzylsulfanyl-2-(3-benzylsulfanyl-3-methyl-butyrylamino)-propionic acid 
• 153893-80-2 3-Benzylmercapto-3-methyl-butyrylchloride 

Relevant articles and documents

FATTY ACID CYSTEAMINE CONJUGATES OF CFTR MODULATORS AND THEIR USE IN TREATING MEDICAL DISORDERS

The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such as a disease caused

Synthesis and characterization of an unsymmetrical cobalt(III) active site analogue of nitrile hydratase

The design, synthesis, and characterization of an unsymmetrical diamidato-dithiol ligand (H4 1, where the hydrogen atoms represent deprotonatable amide and thiol protons) and its cobalt(III) complex, a synthetic analogue of the cobalt-containin

Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

HYDROXYALKYLQUINOLINE ETHER ACIDS AS LEUKOTRIENE ANTAGONISTS

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina

Synthesis and pharmacological activities of novel cyclic disulfide and cyclic sulfide derivatives as hepatoprotective agents

In order to search for anti-hepatitis drugs, we synthesized a series of eight- and nine-membered cyclic disulfides (1) and six- and seven-membered cyclic sulfides (2) and evaluated them for ability to reduce mortality in the model of acute hepatic failure

Synthetic Approaches towards the Novel 1,3-Dioxo-1,2-dithiolane Moiety in the Antitumour Antibiotic Substance Leinamycin

A number of complementary synthetic approaches to the β-thiolactone intermediate 9 for elaboration to the novel 1,3-dioxo-1,2-dithiolane moiety 6 found in the antitumour antibiotic substance leinamycin 1 are described.Thus, deprotection of the benzylthio ether produced from 3-methylbut-2-enoic acid and toluene-α-thiol, leads to the mercapto acid 12 which on cyclisation produces the thiolactone 13. α-Methylation of the thiolactone 13, followed by α-oxygenation then gives rise to the substituted β-thiolactone 9.The β-thiolactone 9 is also produced when: (i) thesodium glycidate 17 is stirred with sodium sulfide leading to 18, followed by thiolactonisation; (ii) thioacetone is treated with the ketene derived from 2-acetoxypropanoyl chloride; and (iii) by irradiation of 3-methyl-2-trimethylsilyloxybut-2-ene 22 with thiophosgene leading to 23, followed by hydrolysis.The β-thiolactone 9 is then converted in three steps into the 1,3-dioxo-1,2-dithiolane 6 by: (i) ring opening to the thioic acid 15, using hydrogen sulfide-triethylamine; (ii) ring closure of 15 to 8 in the presence of aqueous ferric chloride; and finally (iii) oxidation using dimethyldioxirane.Treatment of the ethyl glycidate 19 with disodium disulfide in hot ethanol for 3 days provides the 1,2-dithiolane 8 directly, but in low yields (11-15percent).When the aforementioned reaction sequences are translated to the glycidate 24, derived from 4-methylcyclohex-3-enone and α-chloropropanoic acid, the syntheses of the key intermediates 25, 27 and 26 en route to the spiro-fused 1,3-dioxo-1,2-dithiolane 7 and leinamycin 1 (see Scheme 1) were secured.